Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting

First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.(1)

Detalles Bibliográficos
Autores principales: Chien, A. Jo, Kyalwazi, Beverly, Esserman, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245052/
https://www.ncbi.nlm.nih.gov/pubmed/35732146
http://dx.doi.org/10.1016/j.xcrm.2022.100664
_version_ 1784738664475000832
author Chien, A. Jo
Kyalwazi, Beverly
Esserman, Laura J.
author_facet Chien, A. Jo
Kyalwazi, Beverly
Esserman, Laura J.
author_sort Chien, A. Jo
collection PubMed
description First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.(1)
format Online
Article
Text
id pubmed-9245052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92450522022-07-01 Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting Chien, A. Jo Kyalwazi, Beverly Esserman, Laura J. Cell Rep Med Spotlight First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.(1) Elsevier 2022-06-21 /pmc/articles/PMC9245052/ /pubmed/35732146 http://dx.doi.org/10.1016/j.xcrm.2022.100664 Text en © 2022 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Spotlight
Chien, A. Jo
Kyalwazi, Beverly
Esserman, Laura J.
Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
title Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
title_full Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
title_fullStr Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
title_full_unstemmed Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
title_short Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
title_sort optimizing hormone therapy for breast cancer: translating gains to the early-stage setting
topic Spotlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245052/
https://www.ncbi.nlm.nih.gov/pubmed/35732146
http://dx.doi.org/10.1016/j.xcrm.2022.100664
work_keys_str_mv AT chienajo optimizinghormonetherapyforbreastcancertranslatinggainstotheearlystagesetting
AT kyalwazibeverly optimizinghormonetherapyforbreastcancertranslatinggainstotheearlystagesetting
AT essermanlauraj optimizinghormonetherapyforbreastcancertranslatinggainstotheearlystagesetting

Ejemplares similares